# Efficacy and Safety Study of Dupilumab in Patients With Persistent Asthma

> **NCT03782532** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 486 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Dupilumab SAR231893
- **DRUG:** Placebo
- **DRUG:** Asthma Controller Therapies (include prednisone/prednisolone)
- **DRUG:** Asthma Reliever Therapies

## Key facts

- **NCT ID:** NCT03782532
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-25
- **Primary completion:** 2022-05-21
- **Final completion:** 2022-05-21
- **Target enrollment:** 486 (ACTUAL)
- **Last updated:** 2022-12-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03782532

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03782532, "Efficacy and Safety Study of Dupilumab in Patients With Persistent Asthma". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT03782532. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*